Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 301–400 of 711
Pioglitazone – Do we really need it to manage type 2 diabetes?
Sinha, B., & Ghosal, S. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.06.005 · Cited by 22
Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21
Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome
Moscatiello, S., Luzio, R. D., Sasdelli, A. S., & Marchesini, G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629188 · Cited by 21
Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial Carcinoma
Sanchez, D. J., Missiaen, R., Skuli, N., Steger, D. J., & Simon, M. C. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0189 · Cited by 21
Hong, A.-R., Lee, J., Ku, E. J., Hwangbo, Y., Kim, K. M., Moon, J. H., Choi, S. H., Jang, H. C., & Lim, S. K. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.04.019 · Cited by 21
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Dejager, S., Schweizer, A., & Foley, J. E. (2012) · Vascular Health and Risk Management · doi:10.2147/vhrm.s31758 · Cited by 21
Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings
Niyomnaitham, S., Page, A., Caze, A. L., Whitfield, K., & Smith, A. J. (2014) · BMC Health Services Research · doi:10.1186/1472-6963-14-151 · Cited by 21
Rosiglitazone is not associated with an increased risk of bladder cancer
Tseng, C. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.03.013 · Cited by 21
New tetrazoloquinolinyl methoxyphenyl-4-thiazolidinones: synthesis and antihyperglycemic evaluation
Deshmukh, A. R., Bhosle, M. R., Khillare, L. D., Dhumal, S. T., Mishra, A., Srivastava, A. K., & Mane, R. A. (2016) · Research on Chemical Intermediates · doi:10.1007/s11164-016-2686-5 · Cited by 21
Grillier‐Vuissoz, I., & Mazerbourg, S. (2012) · Journal of Carcinogenesis & Mutagenesis · doi:10.4172/2157-2518.s8-002 · Cited by 21
Evolving Therapeutic Options for Type 2 Diabetes Mellitus: An Overview
Guthrie, R. M. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2614 · Cited by 20
Ryder, R. E. J. (2011) · The British Journal of Diabetes · doi:10.1177/1474651411412658 · Cited by 20
Kakazu, E., Kondo, Y., Ninomiya, M., Kimura, O. S., Nagasaki, F., Ueno, Y., & Shimosegawa, T. (2012) · Hepatology International · doi:10.1007/s12072-012-9395-y · Cited by 20
Afzali, N., Ebadi, S. S., Afzali, H., Sharif, M. R., Vazirian, M., Ebadi, S. A., Shahkarami, V., & Rahimi, H. (2020) · Hepatitis Monthly · doi:10.5812/hepatmon.102125 · Cited by 20
Type 2 diabetes and cancer: problems and suggestions for best patient management
Milluzzo, A., Vigneri, P. G., Martorana, F., Vigneri, R., & Sciacca, L. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00013 · Cited by 20
Tseng, C.-H. (2022) · International Journal of COPD · doi:10.2147/copd.s345796 · Cited by 20
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 20
Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia
Marchesini, G., Forlani, G., Groszmann, R. J., Iwakiri, Y., & Taddei, T. H. (2012) · Hepatology · doi:10.1002/hep.25646 · Cited by 19
Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma
Weidner, P., Söhn, M., Schroeder, T., Helm, L., Hauber, V., Gutting, T., Betge, J., Röcken, C., Rohrbacher, F. N., Pattabiraman, V. R., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0238-8 · Cited by 19
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Tomlinson, B., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1985465 · Cited by 19
Wang, F., Liu, Y., & Bi, Z. (2016) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2016.1171341 · Cited by 19
Beyond diabetes mellitus: role of metformin in non-muscle-invasive bladder cancer
Wang, Z., Ong, W., Shen, T., Sng, J., Lata, R., Mahendran, R., Esuvaranathan, K., & Chiong, E. (2020) · Singapore Medical Journal · doi:10.11622/smedj.2020121 · Cited by 19
Tseng, C. (2013) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2013.04.019 · Cited by 18
Emerging drugs for non-alcoholic steatohepatitis
Tomeno, W., Yoneda, M., Imajo, K., Ogawa, Y., Kessoku, T., Saito, S., Eguchi, Y., & Nakajima, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.811232 · Cited by 18
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Davidson, M. B. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.004 · Cited by 18
Lewis, S. N., Garcia, Z., Hontecillas, R., Bassaganya-Riera, J., & Bevan, D. R. (2015) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-015-9831-x · Cited by 18
Pai, S. A., & Kshirsagar, N. A. (2016) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_650_15 · Cited by 18
Maestra, S. L., Micale, R. T., Flora, S. D., D’Agostini, F., Ganchev, G., Iltcheva, M., Petkov, N., Steele, V. E., & Balansky, R. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs314 · Cited by 18
Pioglitazone and the risk of bladder cancer
Hillaire‐Buys, D., & Faillie, J. (2012) · BMJ · doi:10.1136/bmj.e3500 · Cited by 18
Peroxisome proliferator-activated receptor antagonists as emerging therapeutics in cancer treatment
Misal, S., Patil, V. M., Ramaa, C. S., & Lavecchia, A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108693 · Cited by 17
Exploring the Relation Between Diabetes and HIV: A Narrative Review
Kumar, M., Singh, H., & Chakole, S. V. (2023) · Cureus · doi:10.7759/cureus.43909 · Cited by 17
Reynolds, K., An, J., Wu, J., Harrison, T. N., Wei, R. X., Stuart, B., Martin, J. P., Wlodarczyk, C. S., & Rajpathak, S. N. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.07.021 · Cited by 17
Cofilin 1 promotes bladder cancer and is regulated by TCF7L2
Wang, F., Wu, D., Fu, H., He, F., Xu, C., Zhou, J., Li, D., Li, G., Xu, J., Wu, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20664 · Cited by 17
Glycemic Targets and Medication Limitations for Type 2 Diabetes Mellitus in the Older Adult
Thompson, A. M., Linnebur, S. A., Griend, J. P. V., & Saseen, J. J. (2014) · The Consultant Pharmacist · doi:10.4140/tcp.n.2014.110 · Cited by 17
Nitro-fatty acids as novel electrophilic ligands for peroxisome proliferator-activated receptors
Ferreira, A. M., Minarrieta, L., Lamas Bervejillo, M., & Rubbo, H. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.08.572 · Cited by 16
Drug utilization, safety and clinical use of Actos and Avandia
Marks, D. H. (2013) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-120581 · Cited by 16
Use of thiazolidinedione and cancer risk in Type 2 diabetes: The Hong Kong diabetes registry
Yang, X., So, W., Ronald, C. W., Yu, L. W. L., Kong, A. P. S., Lee, H. M., Xu, G., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.03.006 · Cited by 16
Pioglitazone—Do we really need it to manage type 2 diabetes?
Sinha, B., & Ghosal, S. (2013) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.02.033 · Cited by 16
Bladder cancer with pioglitazone: A case–control study
Malhotra, B., Hiteshi, P., Khalkho, P., Malik, R., Bhadada, S. K., Bhansali, A. K., Shafiq, N., Malhotra, S., Kumar, N., Rajput, R., et al. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102637 · Cited by 16
An update on diagnosis and therapeutics for type-2 diabetes mellitus
Babu, S. (2023) · Bioinformation · doi:10.6026/97320630019295 · Cited by 16
Pantalone, K. M., Hobbs, T. M., Wells, B. J., Kong, S. X., Kattan, M. W., Bouchard, J. R., Chagin, K. M., Yu, C., Sakurada, B., Milinovich, A., et al. (2016) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s39761 · Cited by 16
Qu, H., Zheng, Y., Wang, Y., Zhang, R., Ruan, X. Z., Yang, G., Liu, Z., & Zheng, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-16074-1 · Cited by 16
Rapuano, R., Ziccardi, P., Cioffi, V., Dallavalle, S., Moricca, S., & Lupo, A. (2021) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2021.129973 · Cited by 16
Diabetes medications and cancer risk: review of the literature.
Nguyen, Q. P. H., Sanders, L., Michael, A. P., Anderson, S. R., Nguyen, L. D., & Johnson, Z. A. (2012) · PubMed · Cited by 16
Raz, I., & Eldor, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2265 · Cited by 15
Li, Y., Liu, C., Sun, W.-C., Fan, P.-Y., Liu, F.-H., Chen, T., Wu, V. C., Lin, C., & Hsiao, C.-C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11090828 · Cited by 15
Tseng, C. (2022) · Pharmaceuticals · doi:10.3390/ph15121538 · Cited by 15
Pioglitazone and oral cancer risk in patients with type 2 diabetes
Tseng, C. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.10.015 · Cited by 15
Kim, D., Ahn, B., Kim, Y. S., Hur, D. Y., Yang, J. W., Park, G. B., Jang, J. E., Lee, E. J., Kwon, M. J., Kim, T. N., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2376512 · Cited by 15
Durak-Kozica, M., Paszek, E., & Stępień, E. Ł. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.8 · Cited by 15
Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells
Saad, S., Zhang, J., Yong, R., Yaghobian, D., Wong, M. G., Kelly, D. J., Chen, X., & Pollock, C. A. (2013) · Diabetologia · doi:10.1007/s00125-013-2835-y · Cited by 15
Hampp, C., Greene, P., & Pinheiro, S. P. (2016) · Drug Safety · doi:10.1007/s40264-015-0382-9 · Cited by 14
Modelling cumulative exposure for inference about drug effects in observational studies
Farran, B., McGurnaghan, S. J., Looker, H. C., Livingstone, S. J., Lahnsteiner, E., Colhoun, H. M., & McKeigue, P. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4327 · Cited by 14
Association Between Pioglitazone and Urothelial Bladder Cancer
Barbalat, Y., Dombrovskiy, V. Y., & Weiss, R. E. (2012) · Urology · doi:10.1016/j.urology.2012.03.032 · Cited by 14
Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus
Chen, T.-Y., & Hsieh, C. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.05.2768 · Cited by 14
Management of diabetes across the course of disease: minimizing obesity-associated complications
Apovian, C. M. (2011) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s24022 · Cited by 14
Recent advances in understanding/management of non-alcoholic steatohepatitis
Pacana, T., & Sanyal, A. J. (2015) · F1000Prime Reports · doi:10.12703/p7-28 · Cited by 14
Spirulina Reverses Histomorphological Changes in Diabetic Osteoporosis in Pioglitazone Treated Rats
Devesh, C. (2012) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s1-006 · Cited by 14
Screening for Adiponectin Secretion Regulators
Hino, K., & Nagata, H. (2012) · Vitamins and hormones · doi:10.1016/b978-0-12-398313-8.00005-1 · Cited by 14
Grape Leucoanthocyanidin Protects Liver Tissue in Albino Rabbits with Nonalcoholic Hepatic Steatosis
Franklin, R., Bispo, R. F. M., de Sousa‐Rodrigues, C. F., Pires, L. A. S., Fonseca, A., & Babinski, M. A. (2018) · Cells Tissues Organs · doi:10.1159/000489166 · Cited by 14
Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus
Bethel, M. A., Xu, W., & Theodorakis, M. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12401 · Cited by 13
Berberis integerrima ameliorates insulin resistance in high- fructose-fed insulin-resistant rats.
Fallah, H., Akbari, H., Abolhassani, M., Mohammadi, A., & Gholamhoseinian, A. (2017) · PubMed Central · doi:10.22038/ijbms.2017.9409 · Cited by 13
Hsu, J. C., Ross‐Degnan, D., Wagner, A. K., Zhang, F., & Lu, C. Y. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.04.006 · Cited by 13
Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese
Tseng, C. (2015) · BMC Cancer · doi:10.1186/s12885-015-1057-8 · Cited by 13
Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Papaetis, G. S. (2022) · Current Drug Safety · doi:10.2174/1574886317666220304124756 · Cited by 13
Cellular and molecular effects of thiazolidinediones on bone cells: a review.
Mabilleau, G., Chappard, D., & Baslé, M. F. (2011) · Europe PMC (PubMed Central) · Cited by 13
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Bhushan, S., Ray, R. S., Prakash, J., & Singh, G. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.08.018 · Cited by 12
Ishii, H. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13799 · Cited by 12
Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
Gangopadhyay, K. K., & Singh, A. K. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102747 · Cited by 12
Pan, R., Liu, J., & Chen, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1144918 · Cited by 12
(2011) · Wiley eBooks · doi:10.1002/9781119950424.ch5 · Cited by 12
The durability of sitagliptin in elderly patients with type 2 diabetes
Hsieh, C., & Shen, F. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s72396 · Cited by 12
Ching, J., Amiridis, S., Stylli, S. S., Morokoff, A. P., O'Brien, T. J., & Kaye, A. H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.09.001 · Cited by 12
The path to approval of new drugs for diabetes
Rendell, M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770470 · Cited by 12
Emerging Therapies for Nonalcoholic Fatty Liver Disease
Hameed, B., & Terrault, N. A. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.015 · Cited by 12
Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas
Brooks, L. K., Kalyanaraman, N., & Malek, R. (2018) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.10.033 · Cited by 12
Garry, E. M., Buse, J. B., Gokhale, M., Lund, J. L., Nielsen, M. E., Pate, V., & Stürmer, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13774 · Cited by 12
Shahid, M., Kim, M., Yeon, A., Jin, P., Kim, W., You, S., & Kim, J. (2020) · International Neurourology Journal · doi:10.5213/inj.1938186.093 · Cited by 12
Pioglitazone--where do we stand in India?
Mohan, V., Bedi, S., Unnikrishnan, R., Sahay, B. K., Joshpi, S., & Misra, A. (2012) · PubMed · Cited by 12
Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study.
Dąbrowski, M. (2013) · PubMed · Cited by 12
Yang, X., & Chan, J. C. N. (2011) · Diabetes Care · doi:10.2337/dc11-0627 · Cited by 12
Gor, D., Lee, T. A., Schumock, G. T., Walton, S. M., Gerber, B. S., Nutescu, E. A., & Touchette, D. R. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.1.67 · Cited by 11
Bojková, B., Orendáš, P., Kubatka, P., Péč, M., Kassayová, M., Kisková, T., & Kajo, K. (2014) · Pathology - Research and Practice · doi:10.1016/j.prp.2014.06.003 · Cited by 11
Doupis, J., & Panagoulias, G. S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s34089 · Cited by 11
Rehabilitation of pioglitazone
Ryder, R. E. J., & DeFronzo, R. A. (2015) · The British Journal of Diabetes · doi:10.15277/bjdvd.2015.021 · Cited by 11
Hwang, S., Choi, Y., Wang, J., & Son, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116250 · Cited by 11
Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities
Hashmi, A. (2013) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.119705 · Cited by 11
Identification of PPARγ ligands with One-dimensional Drug Profile Matching
Peitl, B., Kovács, D. K., Simon, Z., Hári, P., Málnási‐Csizmadia, A., Drimba, L., Németh, J., Sári, R. Z., Szilvássy, Z., & Hegedűs, C. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s47173 · Cited by 11
Anti- and Protumorigenic Effects of PPARγin Lung Cancer Progression: A Double-Edged Sword
Li, H. Y., Weiser‐Evans, M. C. M., & Nemenoff, R. A. (2012) · PPAR Research · doi:10.1155/2012/362085 · Cited by 11
Ciglitazone—a human PPARγ agonist—disrupts dorsoventral patterning in zebrafish
Cheng, V., Dasgupta, S., Reddam, A., & Volz, D. C. (2019) · PeerJ · doi:10.7717/peerj.8054 · Cited by 11
Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!
Ziogas, I. A., Zapsalis, K., Giannis, D., & Tsoulfas, G. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i10.709 · Cited by 11
PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes
Milton, F. A., Čvoro, A., Amato, A. A., Sieglaff, D. H., Filgueira, C. S., Arumanayagam, A. S., de Lima, M. D. C. A., Pitta, I. R., Neves, F. D. A. R., & Webb, P. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.011 · Cited by 11
Çubuk, G., & İnce, S. (2015) · Kocatepe Veterinary Journal · Cited by 11
Faillie, J., & Hillaire‐Buys, D. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3925 · Cited by 10
Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes
Tseng, C. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.014 · Cited by 10
Human Insulin Does Not Increase Bladder Cancer Risk
Tseng, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086517 · Cited by 10
Im, H.-J., Hwang, S., Lee, J., Lee, S.-B., Kang, J.-Y., & Son, C. (2020) · Nutrients · doi:10.3390/nu12082433 · Cited by 10
Anonychia due to prenatal phenytoin exposure.
Suresh Babu, M. C., & Agarwal, N. (2012) · PubMed · Cited by 10
Assessment of Pharmacokinetic Interaction of Spirulina with Glitazone in a Type 2 Diabetes Rat Model
Gupta, A. K., Nair, A. B., Kumria, R., Al‐Dhubiab, B. E., Chattopadhyaya, I., & Gupta, S. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2716 · Cited by 10
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.